PARTRIDGE JOHN

SEC source: 0001225208-22-006241 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,177

SEC source: 0001225208-22-003938 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,989

SEC source: 0001225208-21-014399 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,790

SEC source: 0001225208-21-011984 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,543

SEC source: 0001225208-21-008832 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,319

SEC source: 0001225208-21-004295 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,136

SEC source: 0001225208-20-014155 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,910

SEC source: 0001225208-20-011223 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,683

SEC source: 0001225208-20-009771 · doc4.xml · nonDerivative · entry 2

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,416

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020.

F3 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $180.01 to $180.04 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001225208-20-009771 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,216

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020.

F2 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $180.00 to $180.10 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001225208-20-008489 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,916

SEC source: 0001225208-20-004185 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,676

SEC source: 0001225208-19-015093 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,417

SEC source: 0001225208-19-014963 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,180

SEC source: 0001225208-19-012169 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,480

SEC source: 0001225208-19-008813 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,172

SEC source: 0001225208-19-004407 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,852

SEC source: 0001225208-19-002154 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,580

SEC source: 0001567619-18-008657 · doc1.xml · nonDerivative · entry 2

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 0

F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F1 · price: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

SEC source: 0001567619-18-008657 · doc1.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F1 · price: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

SEC source: 0001567619-18-008721 · doc1.xml · nonDerivative · entry 2

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 1,620

F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F1 · price: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

SEC source: 0001567619-18-008721 · doc1.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,580

F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F1 · price: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

SEC source: 0001225208-18-016222 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,580

SEC source: 0001225208-18-013184 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,379

SEC source: 0001225208-18-010123 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,141

SEC source: 0001127602-18-015830 · form4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,156

F1 · kind: Represents fully-vested shares of common stock, which were granted to the reporting person as compensation for service as a non-employee director.

SEC source: 0001225208-18-005161 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,876

SEC source: 0001225208-17-018127 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,647

SEC source: 0001225208-17-014582 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,435

SEC source: 0001225208-17-010847 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,188

SEC source: 0001127602-17-017106 · form4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,784

F1 · kind: Represents fully-vested shares of common stock, which were granted to the reporting person as compensation for service as a non-employee director.

SEC source: 0001225208-17-005391 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,909

SEC source: 0001225208-16-042621 · doc4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,607

SEC source: 0001127602-16-063556 · form4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,984

F1 · kind: Represents fully-vested shares of common stock, which were granted to the reporting person as compensation for service as a non-employee director.

SEC source: 0001127602-12-033869 · form4.xml · nonDerivative · entry 6

PARTRIDGE JOHN · CIK 0001319897 · PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Indirect · By The Partridge Revocable Trust

Disclosed balance after: 0

F3 · price: The price reported in column 4 is a weighted average price. These shares were disposed of in multiple transactions at prices ranging from $148.92 - $149.16, inclusive. The reporting person undertakes to provide to Visa Inc., any security holder of Visa Inc., or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares disposed of at each separate price within the ranges set forth in this Form 4.

SEC source: 0001127602-12-033869 · form4.xml · nonDerivative · entry 5

PARTRIDGE JOHN · CIK 0001319897 · PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Indirect · By The Alison Blackwell Partridge 2004 Irrevocable Trust

Disclosed balance after: 0

SEC source: 0001127602-12-033869 · form4.xml · derivative · entry 11

PARTRIDGE JOHN · CIK 0001319897 · PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 95,622 shares

Expires 2018-11-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: This option was granted on November 5, 2008 and vested in three installments over a three-year period after the date of grant.

SEC source: 0001127602-12-033869 · form4.xml · derivative · entry 10

PARTRIDGE JOHN · CIK 0001319897 · PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,050 shares

Expires 2018-03-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option was granted on March 18, 2008 and vested in three installments over a three-year period after the date of grant.

SEC source: 0001127602-12-033869 · form4.xml · nonDerivative · entry 4

PARTRIDGE JOHN · CIK 0001319897 · PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,178

F2 · price: The price reported in column 4 is a weighted average price. These shares were disposed of in multiple transactions at prices ranging from $149.03 - $150.22, inclusive. The reporting person undertakes to provide to Visa Inc., any security holder of Visa Inc., or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares disposed of at each separate price within the ranges set forth in this Form 4.

SEC source: 0001127602-12-033869 · form4.xml · nonDerivative · entry 3

PARTRIDGE JOHN · CIK 0001319897 · PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,850

F1 · price: The price reported in column 4 is a weighted average price. These shares were disposed of in multiple transactions at prices ranging from $148.84 - $150.23, inclusive. The reporting person undertakes to provide to Visa Inc., any security holder of Visa Inc., or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares disposed of at each separate price within the ranges set forth in this Form 4.

SEC source: 0001127602-12-033869 · form4.xml · nonDerivative · entry 2

PARTRIDGE JOHN · CIK 0001319897 · PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,475

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-033869 · form4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,853

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-032814 · form4.xml · derivative · entry 10

PARTRIDGE JOHN · CIK 0001319897 · PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,299

Underlying: Common Stock · 24,298 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value.

F3 · derivative.exercise_date: Represents performance share awards granted and earned pursuant to the Visa Inc. 2007 Equity Incentive Compensation Plan. The earned performance share award vests in two equal installments on November 30, 2012 and 2013, respectively.

F3 · derivative.expiration_date: Represents performance share awards granted and earned pursuant to the Visa Inc. 2007 Equity Incentive Compensation Plan. The earned performance share award vests in two equal installments on November 30, 2012 and 2013, respectively.

SEC source: 0001127602-12-032814 · form4.xml · derivative · entry 9

PARTRIDGE JOHN · CIK 0001319897 · PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,080 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value.

F2 · derivative.exercise_date: Represents performance share awards granted and earned pursuant to the Visa Inc. 2007 Equity Incentive Compensation Plan. The earned performance share award vested in two equal installments on November 30, 2011 and 2012, respectively.

F2 · derivative.expiration_date: Represents performance share awards granted and earned pursuant to the Visa Inc. 2007 Equity Incentive Compensation Plan. The earned performance share award vested in two equal installments on November 30, 2011 and 2012, respectively.

SEC source: 0001127602-12-032814 · form4.xml · nonDerivative · entry 3

PARTRIDGE JOHN · CIK 0001319897 · PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,803

SEC source: 0001127602-12-032814 · form4.xml · nonDerivative · entry 2

PARTRIDGE JOHN · CIK 0001319897 · PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,786

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-032814 · form4.xml · nonDerivative · entry 1

PARTRIDGE JOHN · CIK 0001319897 · PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,488

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-032480 · form4.xml · derivative · entry 7

PARTRIDGE JOHN · CIK 0001319897 · PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,597

Underlying: Common Stock · 23,534 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value.

F2 · derivative.exercise_date: Represents performance share awards earned at the completion of the performance period pursuant to the Visa Inc. 2007 Equity Incentive Compensation Plan. The earned performance share award vests in two equal installments on November 30, 2012 and 2013, respectively.

F2 · derivative.expiration_date: Represents performance share awards earned at the completion of the performance period pursuant to the Visa Inc. 2007 Equity Incentive Compensation Plan. The earned performance share award vests in two equal installments on November 30, 2012 and 2013, respectively.

SEC source: 0001127602-12-031911 · form4.xml · derivative · entry 8

PARTRIDGE JOHN · CIK 0001319897 · PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,149

Underlying: Common Stock · 5,149 shares

Expires 2022-11-19

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest in three equal installments on each of the first three anniversaries of the date of the grant, subject to earlier vesting in full in limited circumstances as specified in the award agreement.

F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest in three equal installments on each of the first three anniversaries of the date of the grant, subject to earlier vesting in full in limited circumstances as specified in the award agreement.

SEC source: 0001127602-12-031911 · form4.xml · derivative · entry 7

PARTRIDGE JOHN · CIK 0001319897 · PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,345

Underlying: Common Stock · 19,345 shares

Expires 2022-11-19

F1 · derivative.exercise_date: Options vest in three equal installments on each of the first three anniversaries of the date of the grant, subject to earlier vesting in full in limited circumstances as specified in the award agreement.